Health
Results: 4765-4776 of 8802

Zentiva secures approx. 85.27% of APONTIS PHARMA AG voting rights in the context of its public purchase offer

Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia






